Ramadhani Muhammad Zaniar, Kloping Yudhistira Pradnyan, Rahman Ilham Akbar, Yogiswara Niwanda, Renaldo Johan, Wirjopranoto Soetojo
Department of Urology, Faculty of Medicine, Universitas Airlangga, Indonesia.
Dr. Soetomo General-Academic Hospital, Mayjen Prof. Dr. Moestopo No.6-8, Surabaya, 60286, Indonesia.
Ann Med Surg (Lond). 2022 Aug 12;81:104280. doi: 10.1016/j.amsu.2022.104280. eCollection 2022 Sep.
The use of HoLEP was associated with steep learning curve thus prolonging operative procedure. The problem of learning curve could be solved with the invention of Moses HoLEP. This study aimed to evaluate the comparison of efficacy and safety between Moses HoLEP and standard HoLEP in BPH patient.
Systematic search was carried out using PRISMA guideline. Pubmed, Scopus and Embase were searched to collect randomized controlled trials and observational studies. Quantitative analysis was performed to evaluate the comparison in intraoperative, postoperative and complications characteristics. RevMan 5.4 and STATA were used in data analysis.
Total of 7 studies (1226 patients) were included. Regarding intraoperative characteristics, Moses HoLEP provided significantly shorter enucleation time (MD: 3.00, 95% CI: 5.57 to -0.43, p = 0.02), shorter hemostasis time (MD: 3.79, 95% CI: 5.23 to -2.34, p < 0.00001), and shorter laser use time (MD: 2.79, 95% CI: 5.03 to -0.55, p = 0.01). For postoperative characteristics, Moses HoLEP possessed significantly lower PVR (MD -34.57, 95% CI -56.85 to -12.30, p = 0.002). Overall complication was higher in standard HoLEP although the result was not significant (MD 0.68, 95%CI: 0.38 to 1.21, p = 0.19). Moses HoLEP possessed more superiority over standard HoLEP regarding shorter hemostasis time with the increasing of prostate size (coefficient -0.894, p = 0.044).
Moses HoLEP demonstrated shorter enucleation time, shorter hemostasis time and shorter laser use time. Moses HoLEP also possessed lower PVR. There were no safety issues in Moses HoLEP compared with standard HoLEP.
钬激光前列腺剜除术(HoLEP)的应用与陡峭的学习曲线相关,从而延长了手术时间。摩西HoLEP的发明可以解决学习曲线的问题。本研究旨在评估摩西HoLEP与标准HoLEP在良性前列腺增生(BPH)患者中的疗效和安全性比较。
按照PRISMA指南进行系统检索。检索了PubMed、Scopus和Embase以收集随机对照试验和观察性研究。进行定量分析以评估术中、术后及并发症特征方面的比较。数据分析使用RevMan 5.4和STATA。
共纳入7项研究(1226例患者)。关于术中特征,摩西HoLEP的剜除时间显著更短(MD:3.00,95%CI:5.57至-0.43,p = 0.02),止血时间更短(MD:3.79,95%CI:5.23至-2.34,p < 0.00001),激光使用时间更短(MD:2.79,95%CI:5.03至-0.55,p = 0.01)。对于术后特征,摩西HoLEP的残余尿量(PVR)显著更低(MD -34.57,95%CI -56.85至-12.30,p = 0.002)。标准HoLEP的总体并发症更高,尽管结果不显著(MD 0.68,95%CI:0.38至1.21,p = 0.19)。随着前列腺体积增大,摩西HoLEP在止血时间更短方面比标准HoLEP具有更多优势(系数-0.894,p = 0.044)。
摩西HoLEP显示出更短的剜除时间、更短的止血时间和更短的激光使用时间。摩西HoLEP的残余尿量也更低。与标准HoLEP相比,摩西HoLEP没有安全问题。